Fairvalue-Calculator Fairvalue-Calculator
EN DE

Neon Bloom, Inc (NBCO) Fair Value & Analysis

Healthcare · US · Market cap $1.3M

Price$0.0060
Fair Value$0.0061
Upside+1.7%
Quality95/100
Evidence: Medium Range $0.0060 – $0.0066

Fair value as of: Jun 26, 2026

Analysis

Neon Bloom, Inc (NBCO) currently trades at $0.0060, while our model-based Fair Value estimate is $0.0061 — implying the stock looks roughly 1.7% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

About the company

Neon Bloom, Inc. is a principal investment firm specializing in acquisitions. The firm primarily invests in innovative agriculture and ancillary technology products and services across the globe. Neon Bloom, Inc was founded in 2015 and is based in New York, New York.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -38% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -28% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) -28% Alnylam Pharmaceuticals, Inc (ALNY) -63%

Frequently asked questions

Is Neon Bloom, Inc (NBCO) undervalued?
As of Jun 26, 2026, our model estimates a fair value of $0.0061 versus a price of $0.0060 — about +2% (undervalued). Model-based estimate, not financial advice.
What is the fair value of NBCO?
Our 21-model fair value for Neon Bloom, Inc is $0.0061 (as of Jun 26, 2026), built from audited fundamentals. The current price is $0.0060.
What is the quality score of NBCO?
Neon Bloom, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.